Cargando…

Accuracy of controlled attenuation parameter measurement for the detection of steatosis in autoimmune liver diseases

BACKGROUND & AIMS: Concurrent fatty liver disease represents an emerging challenge in the care of individuals with autoimmune liver diseases (AILD). Therefore, we aimed to validate the ultrasound-based method of controlled-attenuation parameter (CAP) as a non-invasive tool to detect hepatic stea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steinmann, Silja, Hartl, Johannes, Weidemann, Sören, Füssel, Katja, Kroll, Claudia, Sebode, Marcial, Lohse, Ansgar Wilhelm, Schramm, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632533/ https://www.ncbi.nlm.nih.gov/pubmed/37954487 http://dx.doi.org/10.1016/j.jhepr.2023.100898

Ejemplares similares

Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care
por: Rüther, Darius Ferenc, et al.
Publicado: (2022)

Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis
por: Sebode, Marcial, et al.
Publicado: (2019)

“Autoimmune(-Like)” Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis
por: Sebode, Marcial, et al.
Publicado: (2017)

SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
por: Duengelhoef, Paul, et al.
Publicado: (2022)

Metamizole: An underrated agent causing severe idiosyncratic drug‐induced liver injury
por: Sebode, Marcial, et al.
Publicado: (2020)

Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver
por: Preti, Max, et al.
Publicado: (2021)

B cells in autoimmune hepatitis: bystanders or central players?
por: Schultheiß, Christoph, et al.
Publicado: (2022)

Prevalence of COVID‐19 in patients with autoimmune liver disease in Europe: A patient‐oriented online survey
por: Zecher, Britta Franziska, et al.
Publicado: (2021)

Autoantibodies in Autoimmune Liver Disease—Clinical and Diagnostic Relevance
por: Sebode, Marcial, et al.
Publicado: (2018)

Immune signatures in variant syndromes of primary biliary cholangitis and autoimmune hepatitis
por: Schultheiß, Christoph, et al.
Publicado: (2023)

Accuracy of attenuation imaging in the assessment of pediatric hepatic steatosis: correlation with the controlled attenuation parameter
por: Kim, Pyeong Hwa, et al.
Publicado: (2022)

SARS-CoV-2 infection in patients with autoimmune hepatitis
por: Marjot, Thomas, et al.
Publicado: (2021)

Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure
por: Zenouzi, Roman, et al.
Publicado: (2018)

Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis
por: Peiseler, Moritz, et al.
Publicado: (2018)

IFNγ and CTLA-4 Drive Hepatic CD4 T-Cell Tolerance and Protection From Autoimmunity in Mice
por: Krzikalla, Daria, et al.
Publicado: (2023)

Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases
por: Ni, Xi-Xi, et al.
Publicado: (2021)

New foe treated with old guns – supportive role of steroids in the treatment of acute severe hepatitis E
por: Sebode, Marcial, et al.
Publicado: (2014)

Tolerance and autoimmunity in the liver
por: Schramm, Christoph, et al.
Publicado: (2022)

Accuracy of controlled attenuation parameter compared with ultrasound for detecting hepatic steatosis in children with severe obesity
por: Runge, Jurgen H., et al.
Publicado: (2020)

Features and outcome of AIH patients without elevation of IgG
por: Hartl, Johannes, et al.
Publicado: (2020)

Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease
por: Jung, Kyu Sik, et al.
Publicado: (2014)

Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis
por: Ehlken, Hanno, et al.
Publicado: (2016)

The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: a diagnostic accuracy study
por: Jiang, Meijuan, et al.
Publicado: (2023)

Correction: Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease
Publicado: (2014)

Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference
por: Kozłowska-Petriczko, Katarzyna, et al.
Publicado: (2021)

Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis
por: Laschtowitz, Alena, et al.
Publicado: (2021)

Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?
por: Sirli, Roxana, et al.
Publicado: (2021)

Usefulness of the Controlled Attenuation Parameter for Detecting Liver Steatosis in Health Checkup Examinees
por: Kim, Ja Kyung, et al.
Publicado: (2015)

The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter
por: Lee, Hye Won, et al.
Publicado: (2017)

Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter
por: Ferraioli, Giovanna, et al.
Publicado: (2017)

Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens)
por: Ferraioli, Giovanna
Publicado: (2021)

Reproducibility of ultrasound-guided attenuation parameter (UGAP) to the noninvasive evaluation of hepatic steatosis
por: Zhao, Yanan, et al.
Publicado: (2022)

Validating controlled attenuation parameter in the assessment of hepatic steatosis in living liver donors
por: Broering, Dieter, et al.
Publicado: (2021)

Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter
por: Shimizu, Kohei, et al.
Publicado: (2018)

A new visual quantitative assessment of ultrasound attenuation parameters for the mild liver steatosis
por: Ren, Xinping, et al.
Publicado: (2022)

Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
por: Wang, Dongxu, et al.
Publicado: (2023)

Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE‐LIVER online survey
por: Wunsch, Ewa, et al.
Publicado: (2022)

Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
por: Hsu, Po-Ke, et al.
Publicado: (2021)

Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis
por: Keller, Sarah, et al.
Publicado: (2018)

Accuracy of the ultrasound attenuation coefficient for the evaluation of hepatic steatosis: a systematic review and meta-analysis of prospective studies
por: Jang, Jong Keon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6sh4v3pn1iunh13kp43j2nlklf